EA201690686A1 - Способ профилактики или лечения системной красной волчанки и/или волчаночного нефрита - Google Patents

Способ профилактики или лечения системной красной волчанки и/или волчаночного нефрита

Info

Publication number
EA201690686A1
EA201690686A1 EA201690686A EA201690686A EA201690686A1 EA 201690686 A1 EA201690686 A1 EA 201690686A1 EA 201690686 A EA201690686 A EA 201690686A EA 201690686 A EA201690686 A EA 201690686A EA 201690686 A1 EA201690686 A1 EA 201690686A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lupine
jade
prevention
treatment
systemic red
Prior art date
Application number
EA201690686A
Other languages
English (en)
Inventor
Тору Кавамура
Ясуси Фудзитани
Масаюки Такидзава
Original Assignee
Милленниум Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Милленниум Фармасьютикалз, Инк. filed Critical Милленниум Фармасьютикалз, Инк.
Publication of EA201690686A1 publication Critical patent/EA201690686A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

В настоящем изобретении представлен способ профилактики или лечения системной красной волчанки и/или волчаночного нефрита у пациента, нуждающегося в этом, включающий введение пациенту эффективного количества [(1R)-1-({[(2,5-дихлорбензоил)амино]ацетил}амино)-3-метилбутил]бороновой кислоты или ее цитратного сложного эфира, или ее фармацевтически приемлемой соли.
EA201690686A 2013-10-03 2014-10-02 Способ профилактики или лечения системной красной волчанки и/или волчаночного нефрита EA201690686A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361886403P 2013-10-03 2013-10-03
PCT/US2014/058738 WO2015051067A1 (en) 2013-10-03 2014-10-02 Method for the prophylaxis or treatment of systemic lupus erythematosus and/or lupus nephritis

Publications (1)

Publication Number Publication Date
EA201690686A1 true EA201690686A1 (ru) 2016-08-31

Family

ID=51842818

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690686A EA201690686A1 (ru) 2013-10-03 2014-10-02 Способ профилактики или лечения системной красной волчанки и/или волчаночного нефрита

Country Status (10)

Country Link
US (2) US20160250238A1 (ru)
EP (1) EP3052105A1 (ru)
JP (1) JP2016531886A (ru)
KR (1) KR20160058886A (ru)
CN (1) CN105705149A (ru)
BR (1) BR112016007237A2 (ru)
CA (1) CA2925935A1 (ru)
EA (1) EA201690686A1 (ru)
MX (1) MX2016003979A (ru)
WO (1) WO2015051067A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7304944B2 (ja) * 2018-06-27 2023-07-07 アルジャーノン・ファーマスーティカルズ・インコーポレイテッド 腎線維症又は腎疾患の予防又は治療におけるアクタリットの使用
KR102344593B1 (ko) * 2020-05-07 2021-12-29 주식회사 뉴로라이브 우울증 치료를 위한 사이클로세린 및 펜톡시필린 병용 요법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
PT1355910E (pt) 2001-01-25 2011-03-24 Us Of America Represented By The Secretary Dept Of Health And Human Services Formulação de compostos do ácido borónico
KR20160040735A (ko) 2007-08-06 2016-04-14 밀레니엄 파머슈티컬스 인코퍼레이티드 프로테아좀 억제제
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
EA027346B1 (ru) * 2008-06-17 2017-07-31 Милленниум Фармасьютикалз, Инк. Соединения боронатного эфира и его фармацевтические составы
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
AR077033A1 (es) 2009-06-11 2011-07-27 Hoffmann La Roche Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas
CN107266485A (zh) 2010-03-31 2017-10-20 米伦纽姆医药公司 1‑氨基‑2‑环丙基乙硼酸衍生物
TW201309303A (zh) 2011-03-03 2013-03-01 Cephalon Inc 用於治療狼瘡的蛋白酶體抑制劑
EP2723751A1 (en) * 2011-06-22 2014-04-30 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use

Also Published As

Publication number Publication date
CN105705149A (zh) 2016-06-22
US20180099000A1 (en) 2018-04-12
MX2016003979A (es) 2016-06-15
BR112016007237A2 (pt) 2017-09-12
KR20160058886A (ko) 2016-05-25
JP2016531886A (ja) 2016-10-13
EP3052105A1 (en) 2016-08-10
WO2015051067A1 (en) 2015-04-09
CA2925935A1 (en) 2015-04-09
US20160250238A1 (en) 2016-09-01

Similar Documents

Publication Publication Date Title
PH12019501414A1 (en) Amino acid compositions and methods for the treatment of liver diseases
MX2020012595A (es) Composiciones farmaceuticas topicas.
PH12019501339A1 (en) Amino acid compositions and methods for the treatment of muscle diseases and disorders
PH12016502355A1 (en) Pharmaceutical composition
EA201691155A1 (ru) Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств
IN2015DN00376A (ru)
IN2015DN00450A (ru)
MX2021013880A (es) Polimeros enlazados al proton para administracion oral.
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний
PH12016502352A1 (en) Pharmaceutical composition
MX2016002580A (es) Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas.
EA201500851A1 (ru) ЭСТРА-1,3,5(10),16-ТЕТРАЕН-3-КАРБОКСАМИДЫ ДЛЯ ИНГИБИРОВАНИЯ 17β-ГИДРОКСИСТЕРОИД-ДЕГИДРОГЕНАЗЫ (AKR1C3)
EA201591378A1 (ru) Композиции неорганических наночастиц в комбинации с ионизирующим излучением для лечения рака
MX2018006247A (es) Metodos para tratar la enfermedad de alzheimer y trastornos relacionados.
EA201491500A1 (ru) Способы лечения фиброза
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
TW201613578A (en) Pharmaceutical combinations
EA201501054A1 (ru) Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы
WO2014152437A3 (en) Methods of use for an antimicrobial peptide
CN106456621A8 (zh) 用于治疗hcv的方法
MX2015012455A (es) Metodo para el tratamiento de la enfermedad de higado graso.
EA201690686A1 (ru) Способ профилактики или лечения системной красной волчанки и/или волчаночного нефрита
EA201390345A1 (ru) Терапевтическое болеутоляющее средство
MY184269A (en) Broad-spectrum anti-influenza virus therapeutic peptides
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms